Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.

Abstract

PURPOSE:

The purpose of this study was to assess renal function in patients treated with the oral platinum drug JM216 [bisacetato-ammine-dichloro-cyclohexylamine-platinum(IV)], since the effects of JM216 on renal function have only partly been investigated using serum parameters or 51Cr-EDTA clearance. We used a sensitive method that assessed glomerular filtration rate (GFR), effective renal plasma flow (ERPF), and indicators of tubular and glomerular damage.

METHODS:

A group of 24 patients with either non-small-cell lung cancer (NSCLC) stage IIIb/IV or small-cell lung cancer (SCLC), limited disease (LD) or extensive disease (ED), treated with JM216 were studied. All patients had no prior chemotherapy, a performance score < 2, a life expectancy of more than 3 months and normal liver, renal and bone marrow functions before treatment. All patients received oral JM216 120 mg/m2 per day for 5 consecutive days, repeated every 21 days with a maximum of six cycles. In six SCLC patients the dose was escalated to 140 mg/m2 per day after the first cycle. Prior to treatment, after the first cycle and after the end of treatment renal function was assessed by 125I-sodium thalamate and 131-hippurate clearances to determine acute and cumulative changes in GFR and ERPF, respectively. Furthermore, tubular and glomerular damage were assessed by urinary excretion of beta2-microglobulin, lactic dehydrogenase (LDH), alkaline phosphatase (ALP), gamma-glutamyltransferase (GT) and albumin.

RESULTS:

In 20 evaluable patients no significant acute impairment of renal function was observed. Median (range) GFR, ERPF and filtration fraction (FF) before treatment were 101 ml/min (53-164 ml/min), 417 ml/min (227-719 ml/min), and 0.25 (0.19-0.33), respectively. After the first cycle values were 117 ml/min (71-189 ml/min), 418 ml/min (228-709 ml/ min) and 0.28 (0.21-0.33), respectively. Also, no indications of tubular or glomerular damage were found. In four patients renal function was evaluated at the end of treatment (one after three cycles, one after five cycles and two after six cycles). Median (range) GFR, ERPF and FF were 99 ml/min (74-139 ml/min), 401 ml/min (277-496 ml/min) and 0.26 (0.23-0.30), respectively, revealing no delayed nephrotoxicity.

CONCLUSION:

We conclude that oral JM216 shows no nephrotoxicity.

• Authors: E Fokkema, E G de Vries, S Meijer, H J Groen
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 45 Issue 1 Pg. 89-92 ( 2000) ISSN: 0344-5704 [Print] Germany
• PMID: 10647508 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• satraplatin

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Carcinoma, Small Cell (drug therapy)
• Female
• Glomerular Filtration Rate (drug effects)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Organoplatinum Compounds (adverse effects)
• Renal Circulation (drug effects)